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ABSTRACT 
The p53 gene family consists of p53, p63 and p73. The three proteins share a high degree of 
structural similarity in their DNA-binding domains but have rather different functions. The 
tumor suppressor p53 acts as the guardian of the genome and is activated in response to 
cellular stress. p53 is a transcription factor that activates downstream target genes to induce 
cell cycle arrest, senescence or apoptosis. However, the TP53 gene is inactivated by missense 
mutation in about half of human tumors. Therefore, reactivation of mutant p53 is an attractive 
strategy for novel cancer treatment. The mutant p53-reactivating compound PRIMA-1, 
identified in a cellular screen of the NCI Diversity set, suppresses tumor cell growth in a 
mutant p53-dependent manner. The methylated analog PRIMA-1Met, now named APR-246, 
is even more potent. APR-246 has been successfully tested in a phase I/IIa clinical trial. A 
phase II clinical trial in ovarian cancer is ongoing. Both PRIMA-1 and APR-246 are prodrugs 
that are converted to the active compound methylene quinuclidinone (MQ), a Michael 
acceptor that binds covalently to cysteines in p53's DNA-binding domain. 
In paper I, we tested the effect of APR-246 on primary adult skin keratinocytes with p63 
mutations from patients with the EEC developmental syndrome. We showed that APR-246 
can partially rescue morphological defects of the mutant p63-carrying EEC keratinocytes, and 
expression of differentiation and stratification markers. Furthermore, we found that APR-246 
restored the expression of p63 target genes. Our findings demonstrate that APR-246 can also 
target mutant forms of p63.    
In paper II, we found that the Michael acceptor activity of MQ is critical for MQ binding, 
thermostabilization and refolding of mutant p53. We identified Cys277 as a prime binding 
site for MQ in p53. Cysteine to alanine substitution at this position abolished both MQ 
binding and thermostabilization. Moreover, we found that both Cys124 and Cys277 are 
required for APR-246 mediated mutant p53 reactivation in His175 mutant p53-carrying 
tumor cells. 
In paper III, we selected potential thiol-reactive compounds including Michael acceptors, 
primary alcohols, imines and aldehydes, with top p53 selectivity based on datamining of the 
NCI database. Multivariable analysis identified different functional groups associated with 
various features of mutant p53 reactivation. Michael acceptors are more prone to high 
toxicity and thiol reactivity. Alcohols and imines are more associated with p53 refolding. 
Aldehydes are more likely to stabilize p53. These results may facilitate the design of novel 
mutant p53-targeting compounds. 
Paper IV describes a p53-like gene in the hydrothermal annelid Alvinella pompejana. 
Sequence alignment and structure modeling indicated that this p53 homolog is more similar 
to p63 and p73. Consistent with this finding, the DNA-binding domain of Alvinella has high 
thermostability. We identified repacking features in the hydrophobic core of Alvinella p53 
that are associated with its high thermostability. Understanding structural features of p53 
family proteins that govern stability may provide insights for development of mutant p53-
reactivating drugs.  
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1 INTRODUCTION 
1.1 CANCER 
Cancer is one of the most lethal diseases that threaten the health of human beings. There were 
14 million new cases of cancer in the world in 2012 and 8.8 million people worldwide died 
from cancer in 2015 according to the World Health Organization (WHO) 
(http://www.who.int/Topics/cancer/en). Unlike normal cells that differentiate to distinct cell 
types with specific functions and stop growing and die as part of normal physiological 
processes or when damaged, cancer cells grow rapidly before they have had a chance to 
mature, they do not die and essentially become immortal. A tumor can potentially spread to 
other part of the body. 
There are more than 100 different types of cancer. Types of cancer are usually named for the 
organs or tissues where the cancers located, such as brain cancer, lung cancer, etc. or the type 
of cells formed them for example, Squamous cell carcinoma, glioma, etc. All types of cancer 
shares the same features or Hallmarks as defined by Hanahan and Weinberg (Hanahan and 
Weinberg, 2011). (1) Keep dividing signals on; (2) evading from growth suppression; (3) 
avoiding immune destruction; (4) have unlimited replication potential; (5) inducing tumor-
associated inflammatory response that enhances tumorigenesis and progression; (6) invasion 
of cells to surrounding tissues and metastasis; (7) form new blood vessels around the tumor to 
get nutrition; (8) genetically instable; (9) resistant to cell death; (10) altered energy 
metabolism.  
Cancer is a genetic disease that is caused by the alteration of genes. The changes of genes are 
mainly caused by environmental factors, such as, radiation, chemicals, diet and obesity, 
tobacco, infections, etc. The remaining is due to inherited genetics. However, not all the 
genetic changes cause cancer; some of them have nothing to do with cancer or may be just 
the results of cancer. The changes of genes that contribute to carcinogenesis are called 
“driver” of cancer. The “driver” genes mainly belong to three types of genes, DNA repair 
genes, proto-oncogenes and tumor suppressor genes. The alterations of DNA repair genes 
lead to additional mutations and promotion of carcinogenesis. Proto-oncogenes are necessary 
in normal cell growth but can convert to oncogenes when they are altered. Tumor suppressor 
genes are guardians in the body to control cell growth but mutations in those genes may result 
in loss of the supervision functions and even new functions to stimulate tumor growth. 
1.2 CANCER THERAPY 
Surgery, radiotherapy and chemotherapy are most common treatments for cancer and they 
can be used either alone or combined with each other. Surgery is the most effective method 
for isolated, primary solid cancer. In certain cases, patients can be cured by removing the 
tumors and the surrounding tissues as well as associated regional lymphatics. However, 
surgery is not optimal when tumors are hardly reached or metastatic. Radiotherapy is also 
widely used in cancer treatment. It uses ionizing radiation to damage the DNA of cancerous 
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tissues to kill them. Radiotherapy can be used as curative treatment for many types of cancer 
for example early stage head and neck cancer as well as prostate cancer. Traditional 
chemotherapy targets fast dividing cells and disrupts cell mitosis. Most of chemotherapeutic 
drugs kill cancer cells by damaging DNA and inhibiting cellular machinery involved in cell 
division. However, some normal cells also proliferate rapidly such as hair follicles and bone 
marrow thus rendering them sensitive to chemotherapeutic drugs, and subsequently leading to 
side effects. In order to kill only cancer cells but not normal cells, targeted cancer therapy has 
arisen. Instead of inhibiting all types of rapidly dividing cells, targeted cancer therapies 
suppress cancer cells growth by interfering with specific molecular targets involved in 
tumorigenesis. Currently, there are mainly two types of targeted cancer therapies: small 
molecules and monoclonal antibodies. Small molecules act by targeting specific enzymes 
such as tyrosine-kinase inhibitors, blocking growth factors and activating tumor suppressors. 
Monoclonal antibodies act by stimulating patients’ immune system to attack cancer cells.  
1.3 p53 
In 1979, p53 was discovered by several independent groups studying simian virus 40 (SV40). 
However, p53 was mistakenly defined as an oncogene in the beginning. This is because the 
p53 was obtained from the cancer cells was mutant. However, around 1988-89 results from 
several groups showed that wild-type p53 is a tumor suppressor, milestone in this fantastic 
field. The exact molecular mass of p53 is 43.7 kDa. Why its name is p53? The reason is it 
migrates as 53 kDa  band on the SDS–PAGE gel due to the high number of proline residues 
in the protein.  
1.3.1 Structure of p53 
In humans, the TP53 gene is located on chromosome 17p13.1. It contains 11 exons. The 
translation starts from the second exon and generates a 393 amino acid protein. The structure 
of p53 protein is characterized by an N-terminal transactivation domain (TAD), a DNA 
binding domain (DBD) and a C-terminal tetramerazation domain (Figure. 1). 
 
Figure 1. Schematic representation of the p53 protein. 
 
The transactivation domain of p53 consists of two subdomains TAD1 and TAD2. Both 
subdomains contain Φ-X-X-Φ-Φ motifs (Φ indicates  a bulky hydrophobic residue and X is 
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any other residue) but display independent transcriptional activities. TAD1 specifically binds 
to MDM2 (Kussie et al., 1996), which negatively regulates p53 stability. TAD2 interacts with 
the replication protein A (RPA70) that blocks p53 binding to specific DNA (Bochkareva et 
al., 2005). The activity of TAD is regulated by post-translational modification, mainly 
phosphorylation. Phosphorylation of Ser15, Thr18 and Ser20 reduce p53-MDM2 complex 
formation (Bode and Dong, 2004). Phosphorylation of ser46 by HIPK-2 or DYRK-2 affects 
induction of p53 proapoptotic target gene such as p53-regulated Apoptosis-Inducing Protein 1 
(p53AIP1) (Oda et al., 2000). 
Between the transactivation domain and the DNA binding domain there is a proline-rich 
domain that contains five repeats of PXXP sequence. Lack of this region results in deficiency 
in anti-neoplastic agents induced cell death (Baptiste et al., 2002). 
The DNA binding domain of p53 is located from residues 94 to 292. Crystal structure of p53 
shows that the basic structure of p53 DNA binding domain is an immunoglobulin like 
sandwich formed by two anti-parallel β-sheets that contains four and five small β-strands 
respectively (Cho et al., 1994). Loop2 occurs between S4 and S5, and Loop3 occurs between 
S8 and S9 are stabilized by a loop-sheet-helix motif (loop L1, beta-strands S2 and S2', four C 
terminal residues of the extended beta-strand S10, and the helix H2). The motif and two loops 
create the DNA binding surface of p53. Between L2 and L3 there is a zinc atom coordinated 
by Cys176, His179, Cys238 and Cys242, which is critical for maintaining the structure of 
p53 protein. The binding of p53 to DNA can be described in three principal parts: Lys120, 
Cys277 and Arg280 bind to the major groove of DNA; Arg248 bins to minor groove of DNA; 
Ser241, Ala276, Arg273 and Arg283 bind to the backbone of DNA. There are 10 cysteines 
(Figure. 2) in the DNA binding domain of p53 with different solvent accessibilities. Cys277 
and Cys182 are the most accessible cysteines followed by Cys229, Cys242 and Cys124. 
Cys135, Cys141 and Cys275 are buried in the hydrophobic core and have no solvent 
accessibility (Scotcher et al., 2011). 
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Figure 2. Cysteines（Yellow）in p53 the core domain. (PDB ID 2OCJ; figures generated using 
PyMOL). 
Three nuclear localization signals (NSLs) (Shaulsky et al., 1990) were identified in p53 
protein. They together with two nuclear export signals (NESs) (Stommel et al., 1999) regulate 
p53 protein nuclear localization. The tetramerization domain is essential for p53 forming 
tetramers that plays important roles for DNA binding, protein-protein interaction and p53 
degragation (Chene, 2001). The basic C-terminal regulation domain binds to DNA 
nonspecifically but affects the affinity of p53 DBD to its specific binding sequences (Hamard 
et al., 2012).  
1.3.2 Regulation of p53 
In normal unstressed cells, wild-type p53 maintains in a very low level. The p53 protein is 
extremely unstable with a 5 -20 minutes half-life (Giaccia and Kastan, 1998). This is because 
a p53 negative regulator murine double minute 2 (MDM2) that binds to the TAD of p53 and 
leads to p53 degradation. Residues Phe19, Trp23, and Leu26 in p53 are critical for the 
binding (Bottger et al., 1997). Phosphorylation of The18 in p53 TAD abrogates p53-MDM2 
interaction (Sakaguchi et al., 2000; Schon et al., 2002). MDM2 is an E3 ubiquitin ligase that 
induces p53 mono- and polyubiquitination. In unstressed condition, low level of MDM2 
induces p53 monoubiquitination and nuclear export. In stressed condition, p53 upregulates 
MDM2 and overexpressed MDM2 forms complexes with p300/CBP and subsequently 
mediate p53 polyubiqutination (Grossman et al., 1998). Then polyubiquitinated p53 is 
degraded by proteasome. In addition, it has been shown Lysine residues in p53, mainly in the 
C-termini, are important for MDM2 mediated p53 degradation (Rodriguez et al., 2000). 
MDMX, a homolog of MDM2, regulates p53 by binding to p53 TAD and inhibits p53 
transactivation activity. Mouse studies have shown that MDM2/MDMX knockout is 
embryonically lethal but can be rescued by absence of p53 (Jones et al., 1995; Parant et al., 
2001). ARF can stabilize p53 by binding to the RING finger domain of MDM2 to inhibit the 
E3 activity of MDM2 (Honda and Yasuda, 1999). Ribosomal protein L1 binds to and inhibits 
MDM2, leads to p53 stabilization and activation (Lohrum et al., 2003).  
In addition to protein level, p53 is also regulated at mRNA level. Wrap53, an antisense 
regulator of p53, overlaps the first exon of p53. Binding of wrap53α transcript to p53 mRNA 
5’ UTR is responsible for stabilization of p53 mRNA (Mahmoudi et al., 2009). Wig-1 
(Vilborg et al., 2009) and human antigen R (HuR) (Zou et al., 2006) stabilize p53 mRNA by 
binding to the AU-rich elements (ARE) in the 3’ UTR. 
1.3.3 p53 function 
p53 is activated in response to various stresses such as DNA damage, hypoxia, oncogenic 
stress (Halazonetis et al., 2008). Depending on types of and extent of stress stimuli and the 
extent of DNA damage, p53 decides the fate of stressed cells by inducing target genes 
involved in corresponding pathways, including cell cycle arrest, apoptosis and senescence.   
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When the stress is minor and the DNA damage is repairable, p53 transcriptionally activates 
target genes involved in cell cycle arrest such as p21 and 14-3-3σ. p21 inhibits CDK2/cyclin 
E induced phosphorylation of pRb. Once pRb is phosphorylated, E2F will be released from 
the pRb-E2F complex and will activate genes involved in progression to S phase (Delavaine 
and La Thangue, 1999). p53 induces G2/M arrest by repressing Cdc25C, a phosphatase 
activating M-phase specific kinase cdc2/cyclin B (Clair and Manfredi, 2006). Additionally, 
p53 transcriptionally activates 14-3-3σ, which prevents the proper nuclear location of cdc2-
cyclin B1 complex (Hermeking et al., 1997).   
p53 also induces senescence, a permanent cell cycle arrest. When cells become senescent, 
they lose the capacity to proliferate and have a larger and flattened morphology.  Many 
makers are used for identifying senescent cells for example senescence-associated β-
galactosidase (SA-βgal), senescence-associated DNA-damage foci (SDFs), p16, etc 
(Campisi and di Fagagna, 2007). Senescence can be induced by many factors, such as 
dysfunctional telomeres (Victorelli and Passos, 2017), persistent oncogenic signaling (Di 
Micco et al., 2006) and reactive oxygen species (ROS) triggered intracellular oxidative 
damage (Weyemi et al., 2012). Studies have shown inactivation of p53 suppresses senescence 
(Beausejour et al., 2003; Kumar et al., 2011). 
In DNA repair pathway, p53 transcriptional activates DNA damage binding protein 2 
(DDB2), which strongly binds to damaged DNA and facilitates the nucleotide excision repair 
(NER) pathway (Zou et al., 2016). p53 binds to MSH2 involved in DNA-mismatch repair 
(Scherer et al., 1996). 
p53 has been shown to induce autophagy by transactivation of the damage-regulated 
autophagy-modulator (DRAM) (Crighton et al., 2006). Paradoxically, p53 also been shown to 
inhibit autophagy (Tasdemir et al., 2008). p14ARF is a potent inducer of autophagy repressed 
by p53. Inactivation of 53 leads to high expression of p14ARF thereby inducing autophagy 
(Abida and Gu, 2008).  
When the damage is severe and can not be repaired, p53 will induce apoptosis, a programed 
cell death process, to eliminate damaged cells. It is a critical way for suppressing 
tumorigenesis. p53 regulates apoptosis by both extrinsic and intrinsic pathways.  The 
extrinsic pathway recruits death receptors to form Death-Inducing-Signaling-Complex 
(DISC), which leads to caspase cascade activation and to apoptosis. Fas/CD95 is the most 
common death receptor and a key component for extrinsic pathway (Nagata and Golstein, 
1995). Upon p53 transactivation Fas is activated by binding to its ligand FasL and activates 
caspase-8. The intrinsic pathway governs the release of cytochrome-C from the mitochondria 
by Bcl-2 family members such as, Bax, PUMA and Noxa. Once be transactivated by p53, 
Bax translocated to the surface of mitochondria forms homodimer or complex with Bak 
resulting in the release of cytochrome-C and caspase-9 activation (Skulachev, 1998). PUMA 
binds to Bcl-2 family pre-survival members such as Bcl-2 and Bcl-XL leads to Bax and Bak 
activation (Nakano and Vousden, 2001). Noxa induces apoptosis in a similar manner to 
PUMA and Bax. In addition to transcription dependent apoptosis induction, p53 also can 
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localize to mitochondria in cytoplasm and induce mitochondrial outer membrane 
permeabilization (Green and Kroemer, 2009). 
Studies have shown that p53 induces ferroptosis by inhibiting SLC7A11 an important 
component of the cystine/glutamate antiporter, resulting in ROS induction (Jiang et al., 2015; 
Murphy, 2016). It has been shown that p533KR an acetylation-defective mutant was unable to 
induce p53 mediated cell cycle arrest, senescence and apoptosis but still retains tumor 
suppression activity upon ROS upregulation. 
p53 also influences metabolic pathway by regulating genes involved in respiratory and 
glycolytic pathways. For example, TIGAR, TP53-induced glycolysis and apoptosis regulator, 
inhibits glycolysis by decreasing the concentration of fructose-2,6-biphosphate. SCO2, 
synthesis of cytochrome c oxidase 2, promotes oxidative phosphorylation (Puzio-Kuter, 
2011). 
 
Figure 3. p53 regulation and signaling pathways. 
 
1.3.4 p53 family member p63 and p73 
Almost 20 years after p53 discovery, two other family members, p63 and p73 were identified. 
All three family members share a p63/p73 like common ancestor. The function of this 
ancestral gene is conserved during billion year’s evolution, which is protecting the germline 
gametes. Phylogenetic analysis suggested p63, first identified in C. elegans, is the 
evolutionary oldest.  p73 and p53 evolved from it. Like p53 structure, p63 and p73 also 
contain an N-terminal transactivation domain, a DNA binding domain and a C-terminal 
oligomerization domain. The DNA binding domain is highly conserved among all family 
members with more than 60% sequence identity. Because of two transcription start sites in 
the p63/p73 gene, two functional distinct protein isoforms TAp63/p73 and  Δ-Np63/p73 are 
  19 
produced. Studies have shown TAp63 and TAp73 can transactivate many p53 target genes 
and induce apoptosis (Shimada et al., 1999; Zhu et al., 1998). p63 and p73 have an extra 
sterile alpha motif (SAM) domain in the C-terminal, which be thought to mediate protein-
protein interactions and inhibits transactivation activity of their TAD. Depletion of this region 
can enhance TAp63α and TAp73α transactivation activity (Ozaki et al., 1999; Suzuki et al., 
2015). 
TP63 is located on chromosome 3q27-29. p63 is rarely mutated but highly amplified and over 
expressed in human cancer. In addition to N-terminal isoforms, C-terminal alternative 
splicing leads to three additional isoforms α, β and γ. The ΔNp63α protein is predominantly 
expressed isoform in embryonic ectoderm and many epithelial tissues. It is crucial for 
proliferative potential of stem cells and epithelial tissue development. p63 null mice showed 
severer defect of in limb, craniofacial and epithelial development (Romano et al., 2012). 
Mutations in the DNA binding domain of p53 are strongly associated with Ectrodactyly, 
ectodermal dysplasia, and cleft lip/palate (EEC) syndrome. Mutations in p63 at sites 204, 279 
and 304 in EEC syndrome patients correspond to hot spot mutation sites 175, 248 and 273 in 
p53 in human tumors (Celli et al., 1999).  Moreover, it has been shown that p63 also has a 
key role in the control of aging process by downregulating sirt 1 (Sommer et al., 2006). 
TP73 gene is located on chromosome 1p36. Like p63, only few p73 mutations were found in 
human cancer. p73 knockout mice do not develop tumors. However, high expression level of 
Δp73 has been found in many tumor types including neuroblastomas, melanomas, lung 
cancers and hepatocellular carcinomas (Stiewe and Putzer, 2002) and p73 overexpression is 
positively correlated with higher pathological stage and poor survival (Dominguez et al., 
2001; Tannapfel et al., 1999). Studies have shown that p73 is enriched in the nervous system 
and plays an important role in neurological development (Talos et al., 2010). p73 deficient 
mice exhibit neurological and immunological defects (Yang et al., 2000). 
 
Figure 4. Schematic representation of the p53 family isoforms. 
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1.3.5 p53 inactivation and cancer 
TP53 gene is the most frequently mutated gene in human cancer. Germline mutations within 
a defined region of p53 gene are associated with Li-Fraumeni syndrome and Li-Fraumeni like 
syndrome (Varley, 2003). Somatic mutations are found in most types of sporadic human 
cancer. The frequencies are varied from 10% to 90% depending on the type and stage of 
cancer (Figure. 5). The majority of p53 mutations are the missense mutation that accounts for 
75% in human cancer. Frameshift and nonsense mutation each account for 10%. The rest 5% 
are mainly synonymous and splice site mutations. Approximately, 86% of p53 mutations 
occur in the conserved DNA binding domain (Olivier et al., 2010). Six sites (Arg-175, Gly-
245, Arg-248, Arg-249, Arg-273 and Arg-282) represent almost 40% of p53 mutations and 
are defined as hot spot mutations (Olivier et al., 2002). p53 missense mutations are classified 
to two groups, DNA contact mutations and structural mutations. DNA contact mutations, just 
as its name implies, inactivate p53 by affecting the residues involved in DNA binding without 
altering global protein conformation. The examples of these substitutions are R273H, R248Q 
and R248W. Structural mutations such as R175H cause low stability and conformational 
change of p53. In addition to loss of functions (LOF), mutant p53 also gain some functions 
(GOF), by interacting with other proteins such as p63 and p73, thereby promoting tumor cell 
growth. Unlike most of other tumor suppressor genes that mutations in only one allele usually 
do not affect their activity, one allele mutation dramatically abrogates p53 functionality. The 
reason is wild-type p53 acts as a transcription factor as a homotetramer. In cells carrying 
mutations in one allele and the other allele remains wild type, two types of p53 form 
heterotetramers that usually are inactive.  
 
Figure 5. p53 alteration frequency in cancer.  
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In addition to mutation, p53 tumor suppressor functions also can be impaired by 
destabilization of p53 protein.  As descripted above, MDM2 is a key p53 negative regulator 
binds to TAD of p53 that promotes p53 degradation. Amplification of MDM2 gene and over 
expression of MDM2 protein are features of many tumors (Gunther et al., 2000; Oliner et al., 
1992). Viral proteins are also reported inactivate p53 by inducing p53 protein degradation. 
For instance, E6 encoded by human papilloma viruses (HPV) forms complex with p53 and 
targets it for proteasomal degradation (Scheffner et al., 1990; Thomas et al., 1999).  
1.4 RESCUE OF WILD-TYPE P53 FUNCTION FOR CANCER THERAPY 
1.4.1 Activation of wild-type p53 
As described above, in many human tumors p53 is inactivated by MDM2/MDMX mediated 
p53 degradation. Thereby, it is logical to design drugs to reactivate p53 activity by stabilizing 
p53 through disrupting p53-MDM2 interaction. Nutlin, a specific MDM2 inhibitor, mimics 
three hydrophobic residues on p53 required for MDM2 binding. It blocks the binding of 
MDM2 to p53 resulting in  p53 stabilization and activation (Vassilev et al., 2004).  RG7112 
binds MDM2 with a stronger affinity than Nutalin-3a and blocks p53-MDM2 interaction. It 
has been tested in several clinical trials (Kojima et al., 2016). Benzodiazepinediones disrupt 
p53-MDM2 interaction in a similar manner to nutlin (Koblish et al., 2006). RITA, a small 
molecule, has been identified that prevents p53–MDM2 interaction by inducing p53 
conformational change through binding to the N-terminal of p53 (Issaeva et al., 2004). 
Notably, RITA also induces the proteasome-dependent degradation of MDMX (Spinnler et 
al., 2011).  
1.4.2 Reactivation of mutant p53 
The high frequency and high expression level of mutant p53 in human tumors makes it an 
attractive target for cancer therapy. The strategy is to restore and stabilize the native 
conformation of p53 DNA binding domain for specific DNA binding thereby inducing p53 
target gene activation to induce tumor cell apoptosis. Studies have shown p53 can be 
stabilized by introducing a second mutation (Blandino et al., 2012). CDB3, a small peptide 
derived from a p53 binding protein, binds to native but not denatured p53 core domain, shift 
the equilibrium between folded and unfolded protein towards the folded state,  and restores 
specific DNA binding for mutant p53 (Friedler et al., 2002).  Many compounds have been 
identified by chemical library screening, molecular modeling or rational drug design that  can 
restore wild type functions to mutant p53 such as,   CP-31398， MIRA-1, STIMA-1, 
PK11007, ZMC1, stictic acid and PRIMA-1/APR-246 (Bykov et al., 2018). 
CP-31398 was identified by screening a library of synthetic compounds that stabilizes wild-
type p53 conformation and restores wild-type p53 functions to mutant p53 (Foster et al., 
1999; Wischhusen et al., 2003). In vivo study has shown that CP-31398 prevents growth and 
invasion of bladder tumors in transgenic UPII-SV40T mice (Madka et al., 2013).  CP-31398 
 22 
has Michael acceptor activity. N-acetylcysteine (NAC) partially inhibits CP-31398 induced 
growth suppression in H1299His175 cells (Zache et al., 2008).  
MIRA-1 and STIMA-1 were identified by screening molecular libraries that target mutant 
p53 expressing cells and induce p53 target gene activation (Bykov et al., 2005a; Zache et al., 
2008). Both of them are Michael acceptors participate in reactions of nucleophilic addition, 
prone to react with free thiol groups in the cell.  It has been shown that MIRA-1 also induces 
p53-independent growth suppression by caspase 9 activation (Bou-Hanna et al., 2015).  
PK11007, one of 2-sulfonylpyrimidines, is a thiol alkylator that has anti-tumor activity in 
many tumor cell lines. It can act in both p53-dependent and p53-independent manners (GSH 
depletion) (Bauer et al., 2016). Cys182 and Cys277 are crucial for PK11007 mediated mutant 
p53 reactivation.   
ZMC1(NSC319726) as a Zn2+ chelating compound buffers intracellular Zn2+ to an optimal   
concentration for binding to p53, which is crucial for wild-type p53 structural stability. It 
induces PAb1260 (wild-type p53 conformation specific antibody) epitope and p53 dependent 
apoptosis in H1299His175 cells (Yu et al., 2014; Yu et al., 2012). There is an imine group 
which can react with thiol in ZMC1 may contribute to its biological activity. 
Stictic acid was identified by in silico screening that binds to the binding pocket between 
loop L1 and sheet S3 of the p53 core domain. It thermostabilizes R175H and G254S p53 
mutants and induces p53 target gene p21 expression in a dose dependent manner 
(Wassman et al., 2013). 
PRIMA-1 was identified by screening the NCI library of low molecular weight 
compounds that suppresses tumor cell growth in a mutant p53 dependent manner  (Bykov 
et al., 2002). Later on, we found the methylated analog PRIMA-1met/APR-246 is more 
potent.  In vivo studies have shown that PRIMA-1 and APR-246 inhibit growth of tumor 
xenografts expressing mutant p53 in SCID mice (Bykov et al., 2002; Zandi et al., 2011). 
Recent studies have shown APR-246 also induces p53-independent cell death mainly by 
regulating ROS. APR-246 inhibits Thioredoxin reductase (TrxR1) presumably by 
covalent binding to a selenocysteine residue in TrxR1 and contributes to ROS production  
(Peng et al., 2013). MQ binds to cysteine in glutathione (GSH) and forms GS-MQ, 
which significantly reduces the activity of GSH results in ROS accumulation (Liu et al., 
2017; Tessoulin et al., 2014). APR-246 showed synergistic effects with conventional 
chemotherapeutic drugs such as cisplatin, doxorubicin were observed both in vitro and in 
vivo (Bykov et al., 2005b; Liu et al., 2015). A phase I/IIa clinical trial of APR-246 in 
patients with leukaemias, lymphomas or prostate cancer is completed (Lehmann et al., 
2012). This study defined the maximum tolerated dose (MTD) as 60mg/kg and showed 
only minor and transient side effects, including dizziness, fatigue, headache, nausea, and 
confusion. Currently, APR-246 has been tested in a phase II clinical trial in patients with 
high-grade serious ovarian cancer (HGSOC), which is characterized by p53 mutations. 
Furthermore, a clinical trial in Oesophageal cancer patients is ongoing. Studies of APR-
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246 in combination with other drugs are also under way for example, APR-246 
combined with Dabrafenib in melanoma, with Pegylated liposomal Doxorubicin 
Hydrochloride (PLD) in HGSOC, with Azacitidine in patients with Myelodysplastic 
syndrome, acute myeloid leukemia, myeloproliferative neoplasm or chronic 
myelomonocytic leukemia(clinicaltrials.gov). Both PRIMA-1 and APR-246 convert to 
MQ, an electrophile has Michael acceptor activity. The electron-withdrawing carbonyl 
group in MQ makes the carbon-carbon double bond highly reactive that is prone to 
attack thiols. Previous study has shown MQ covalently binds to the cysteines in p53 core 
domain (Lambert et al., 2009). Cysteine to alanine substitution at position 124 in p53 
core domain abolishes APR-246 mediated mutant p53 reactivation (Wassman et al., 
2013).  
 
 
Figure 6. Chemical structure of mutant p53 reactivating compounds. Blue indicates the thiol 
reacting sites.  
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2 AIMS OF THE THESIS 
The general aim of this thesis is to improve drug design and development in cancer treatment 
by studying the structure of p53 family members during evolution and the molecular 
mechanisms of mutant p53 reactivation. 
Specific aims 
Paper I 
To investigate whether APR-246 reactivates mutant p63 in keratinocytes derived from EEC 
syndrome patients. 
 
Paper II 
To elucidate the mechanism of APR-246/MQ-mediated mutant p53 reactivation. 
 
Paper III 
To understand the relationship between thiol reactivity, mutant p53 reactivation and tumor 
cell death.  
 
Paper IV 
To reach a better understanding of the structure of p53 and the factors govern its stability 
during the evolution. 
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3 RESULTS AND DISCUSSIONS 
3.1 PAPER I 
APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from 
EEC syndrome patients with p63 mutations 
p63 shares high sequence and structure similarities with p53. p63 lacks mutation in cancer 
development. Instead, mutations of p63 cause severe defects in epidermal, craniofacial and 
limb development such as ectrodactyly, ectodermal dysplasia, and cleft lip/palate (EEC) 
syndrome. Some p63 mutations associated with EEC syndrome R204W, R279H and R304W 
correspond to hot mutations R175H, R248 W and R273H inp53 respectively. Previously we 
have shown that PRIMA-1/APR-246 restores wild-type p53 activities to mutant p53 to 
induce apoptosis in human tumor cells. In this study, we want to investigate whether APR-
246 reactivates mutant p63 in human keratinocytes derived from EEC syndrome patients.  
We established keratinocyte models derived from EEC syndrome patients carrying p63 
mutations (R204W, R279H or R304W) in the DNA binding domain of p63. By analyzing the 
expression profile, we found the 328 genes showed significant and consistent changes in all 
mutant cells and identified 208 of them are potential p63 target genes. ADH7 is one of these 
genes that the expression was almost lost in cells with p63 mutations in the DNA binding 
domain. We observed that the morphological features of cells with R204W and R304W 
mutations are differ from wild-type p63 cells. Compared to wt cells, mutant p63 cells are 
larger, flatter under proliferative condition. After differentiation, wt cells started forming 
multilayers but mutant p63 cells were either detached or maintained as a single layer.  
 
Figure 7. APR-246 restores morphology of keratinocytes with mutant p63 and reactivates its 
target genes. 
 
Does mutant p53 reactivating compound APR-246 restore wild-type functions to mutant p63 
in EEC patients? To answer this question, we treated mutant p63 keratinocytes in 2D and 3D 
cultures with APR-246. We observed that treatment partially rescued wt morphology in 
mutant p63 cells. Furthermore, we observed induction of markers in epidermal differentiation 
and stratification, such as K1 and K10 in epithelial, involucrin in the spinous layer, TGM, 
CysME, LCE2 and Filaggrin in the granular layer, after APR-246 treatment. Moreover, p63 
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target gene ADH7, GPX2 and Claudin-1 were also induced in both protein and mRNA level 
upon APR-246 treatment. All our observations suggest that APR-246 recues human skin 
epidermal differentiation by restoring wild-type functions to mutant p63. 
Our study may open new insights for screening and designing novel drugs for 
pharmacological treatments for patients with mutant p63 associated developmental disorders 
as wells as other mutant p63 related diseases.  
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3.2 PAPER II 
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 
We have shown than the conversion products of PRIMA-1 bind covalently to cysteines in the 
p53 core domain. However, which cysteines among 10 cysteines in p53 core domain are the 
exact targets for MQ remains unknown.  
Firstly, we found MQ bound to wild-type p53 core domain as well as R175H and R273H 
mutants in a dose dependent manner. However, the inactive analog MQ-H was unable to bind 
any of them.  In accordance with the binding results, we showed MQ but not MQ-H 
enhanced the thermostabilities of wt and mutant p53 core domains by both differential 
scanning fluorimetry (DSF) and circular dichroism (CD). To determine if APR-246/MQ can 
refold mutant p53 in cellular environment we treated TOV-112D ovarian carcinoma cells 
which carrying R175H structure mutant with APR-246/MQ. We observed that APR-246/MQ 
induced PAb1620, a “wt” like structure specific p53 antibody, positive staining and decreased 
mutant p53 structure specific antibody HO3.5 staining. However, MQ-H failed in inducing 
any change in either PAb1620 or HO3.5 staining. All these results indicate that Michael 
acceptor activity of MQ is essential for mutant p53 reactivation. Subsequently we identified 
Cys277 as a prime binding site for MQ by performing mass spectrometry with MQ treated 
p53 core domain proteins contain cysteine (Cys) to alanine (Ala) substitution at sites 124, 
182, 249 or 277. Later on, we found that Cys277 is also essential for MQ mediated 
thermostailization of p53 core domain by performing DSF with these core domains  
To understand the role of cysteine residues in mutant p53 reactivation in living tumor cells, 
we transfected human lung carcinoma H1299 cells with R175H, R175HC124A, R175H 
C277A or R175H-C124A-C277A vectors. After APR-246 treatment, we found that APR-246 
induced Annexin V positive staining in cells transfected R175H construct but not cells with 
C124A or C277A mutations indicated C124A and C277A abolished APR-246 induced 
apoptosis. Furthermore, we want to know if the C124A and C277A can affect APR-246 
induced p53 target gene activation. We found cells transfected with constructs contain C124A 
or C277A mutations showed significantly reduction on the expression of p21, Fas and Bax, 
which is consistent with the failure of apoptosis induction. However, the abolishment of 
apoptosis and p53 target gene activation is plausible due to the damage of p53 activities by 
C124A or C277A substitution. To determine this, we transfected H1299 cells with wt, 
C124A, C277A, R175H or R273H constructs and assessed apoptosis and p21 induction. We 
observed apoptosis as well as p21 induction in cells expressing wt, C124A and C277A p53 
but not in cells with R175H and R273H mutants indicate C124A and C277A do not inactivate 
p53.  
In conclusion, the Michael acceptor activity is essential for MQ to bind, stabilize and refold 
p53. Cys277 as a prime target for MQ is critical for p53 thermostabilization. Both Cys124 
and Cys277 are required for APR-246/MQ mediated MQ induced mutant p53 reactivation in 
living tumor cells. 
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3.3 PAPER III 
Role of thiol reactivity for targeting mutant p53 
Many identified mutant p53 reactivation compounds such as APR-246, MIRA-1 and 
PK11007 share one common feature: having the ability to react with thiols. Is there any 
correlation between thiol-reactivity and mutant p53 reactivation?  
To address this question, we selected potential thiol reactive compounds in the National 
Cancer Institute (NCI; Bethesda, MD) library based on the chemical structure (Michael 
acceptor, imine, primary alcohol and aldehyde) that showed biological activity (IC50<=10-
4M) in at least 3 cell lines in NCI screening. Compounds showed top p53 selectivity, IC50wt/ 
IC50 mutant >=1,4 in all five selected tumor types (leukemia, NSCLC, melanoma, ovarian 
cancer and renal cancer) which contain at least 2 wt p53 expressing cell lines and at least 2 
mutant p53 expressing cell liens, were selected for subsequently studies.    
We performed experiments with H1299/H1299His175 and Saos-2/Saos2His273 cell systems 
to study the ability of each compound to react with thiols and to induce growth suppression, 
subG1 population, cell cycle arrest, mutant p53 refolding, thermostabilization and ROS. A 
complex data matrix was generated from those experiments. In order to get meaningful 
information from the data matrix, we performed multivariate analysis. We identified four 
important factors that explained around 50% of the variability of the data by employing 
standard extraction method communalities = multiple R2 with Kaiser Criterion. Subsequently, we 
performed so called K-mean clustering technique to stratify all the compounds into three 
clusters: Cluster I compounds are characterized as toxic thiol reagents; Cluster II compounds 
are p53 refolders and cluster III are thermostabilizers. To investigate the relationships 
between the functional effects and chemical functional groups we did correspondence 
analysis. We found that compounds with Michael acceptor group either alone or together with 
imine are prone to react with thiols and have high toxicity. p53 refolders are more likely to 
have alcohol groups either alone or combined with imine or combined with imine and 
Michael acceptor functionalities. Aldehyde or imine groups or Michael acceptor combined 
with either aldehyde or alcohol functionality are more likely to contribute to 
thermostabilization.  
In our study, we found the degree of thiol reactivity is critical for mutant p53 targeting 
compounds. Mild thiol reactivity stimulates mutant p53 refolding but too high reactivity often 
leads to general toxicity. Interestingly, we found that compounds with one functional group 
alone or combined with other groups can belong to different clusters for example compounds 
with alcohol groups belong to p53 refolders but compounds with alcohol combined with 
Michael acceptor are more like to be thermostabilizers. A molecule can presumably gain 
desired p53 dependent biophysical or biological effects by judicious design of thiol-reactive 
functionalities. Our study sheds light on a new perspective for developing more potent mutant p53 
targeting drugs.  
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3.4 PAPER IV 
The DNA-binding domain of a p53 homolog from the hydrothermal annelid Alvinella 
pompejana: protein stability and evolutionary history of the p53 family  
In this study, we obtained a transcript containing p53-like DBD by performing a BLAST 
search of the Alvinella pompejana expressed sequence tag (EST) database. The genome 
sequence of this worm is not available yet, but analysis of published genomes of two other 
annelid worms, the marine polychaete Capitella teleta and the freshwater leech Helobdella 
robusta suggests the presence of a single p53 family gene in Alvinella. Capitella and 
Alvinella belong to the same class (polychaetes worms). Prediction of Capitella p53 homolog 
suggests it contains a p63 and p73 characteristic SAM domain. Sequence alignment of 
Alvinella p53 DBD showed that it has high sequence identity with the DBD of human p53 
family members: p53 (47%), p63 (58%) and p73 (56%). The conservation is even higher 
between Alvinella and Capitella, more than 80%. By homology modeling of Alvinella DBD, 
we found that the human p53 corresponding residues in the zinc binding sites (Cys176, 
Cys238, Cys242 and His176) and the key DNA binding sites (Arg282, Arg273 and 280) are 
conserved in Alvinella.  
A double salt bridge formed by Glu180 and Arg181 between two human p53 DBDs is a 
typical motif associated with p53 binding cooperativity. This motif is a typical feature of 
vertebrate p53 except rainbow trout. However, it is missing in human p63/p73, Alvinella 
homolog and other invertebrate p53 homologs. Evolutionary study showed the first 
appearance of this motif is in cartilaginous fishes in the evolutionary tree of p53 family 
proteins. Altogether indicate the double salt bridge is special event of p53 evolution appears 
in early stage of vertebrate. 
To investigate protein thermotability, we performed DSF and DSC with the Alvinella DBD 
and selected vertebrate p53 variant. We found the Alvinella DBD was the most stable one 
among all tested proteins followed by the DBD of chicken. Their Tms were much higher than 
the Tm of the human p53 DBD. However, the DBD of cold-blood frog was less stable than 
the human DBD. The melting temperature of DBD from rainbow trout, a cold-water animal, 
was even lower. The correlation between protein thermotability and the organismal and living 
environmental temperature indicates that p53 has evolved to be more suitable for organisms 
during evolution.  
Why is Alivnella DBD so stable? One possibility could be the high sequence conservation 
with more stable homolog p63, which has an optimal packing of the hydrophobic core. It has 
been shown that packing of hydrophobic core correlates protein stability. F270L mutation in 
the hydrophobic core of the human p53 DBD reduces thermotability and leads to protein 
unfolding and aggregation. Alivnella DBD has a similar large to small substitution F270V. 
However, a neighbor small to large substitution I255F compensates it that maintains the 
optimal packing of hydrophobic core. This inverted packing pattern is found in most of 
invertebrate p53 family sequences, however, all extant vertebrates share the same 255/270 
 32 
packing pattern found in human p53. Moreover, it has been reported that human p53 DBD is 
stabilized by removing the non-saturated hydrogen bond between Y236 and T253. 
Substitutions with equivalent hydrophobic residues were found in more stabled p63/p73 and 
Alvinella DBD. Furthermore, it have been reported that a second site N239Y mutation 
stabilizes human p53 DBD, Phenylalanine at the same position in Avinella DBD may have 
similar packing interactions as tyrosine which stabilizes human N239 mutant.  
In summary, our structural and phylogenetic analysis suggests that the Alvinella p53 homolog 
is more p63/p73 like. The modeling study indicates a series of repacking features of the 
hydrophobic core are associated with its high thermotability. By understanding the structure 
of p53 family members and the factors govern their stabilities in evolution may open new 
insights for us to develop mutant p53 targeting drugs for cancer therapy.  
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4 CONCLUSIONS AND FUTURE PERSPECTIVES 
Transcription factor p53 plays key roles in tumor suppression and regulates various signaling 
pathways involved in this process. p53 mutations are reported in almost all cancer types. The 
mutation frequencies vary from 10% to almost 100%, on average 50%. Therefore, restoration 
wild-type p53 functions to mutant p53 becomes an attractive strategy for cancer treatment 
since the first mutant p53 reactivating compound CP-31398 was identified in 1999.  
In order to design and develop novel and more potent mutant p53 targeting drug we need to 
understand more about p53, including the change of its structural features between wild type 
and mutant states. People believe mutations inactivate p53 by unfolding its structure and 
eventually disrupting its ability to bind to DNA. Many p53 cancer mutations are temperature 
sensitive can be rescued by simply low down the temperature. Interestingly, it has been 
shown that the xenopus p53 protein behaves like the temperature sensitive p53 cancer 
mutants.  Further studies have shown the thermostability of p53 DBD has correlation with the 
body and living environmental temperature of the organism. Avinella is a thermophile. It is 
interesting to study the thermostability of p53 in this worm. In paper IV, we found that p53 
homolog in Avinella is more p63/p73 like. The thermostability of its DBD is much higher 
than human p53 DBD but lower than human p63 DBD. To understand what factors lead to its 
high stability we compared its sequence with human p53, p63 and p73. We found Avinella 
protein has several packing features of the hydrophobic core such as, removing non-saturated 
hydrogen bond, residues form stabilizing packing interaction, are similar to p63, p73 and 
stabilized p53 mutant. It might be feasible to design drugs to govern p53 thermostability by 
modulating the packing of its hydrophobic core.  
p53 and p63 are highly conserved in the DBD. It is logical to study whether mutant p53 
reactivating compound, APR-246 can also reactivate mutant p63. Previous study has shown 
APR-246 can restore wild-type function to mutant TAp63γ in human tumor cells. However, 
p63 is rarely mutated in human cancer. Mutations in p63 are highly associated with many 
human developmental defect syndromes such as, EEC and AEC. In paper I, we found that 
APR-246 could reactivate R204W and R304W mutants and induce p63 target gene 
expression.  In addition, we observed APR-246 rescues the morphology of human 
keratinocytes carrying mutant p53 derived from EEC syndrome patients. However, the 
mechanism of mutant p63 reactivating is unclear. It will be interesting to study whether 
mutations in p63 lead to protein destabilization and unfolding. Whether APR-246 binds to 
p53, if so, where does it bind to p63? Does APR-246 stabilize and refold mutant p63? By 
studying there questions, we will have a better understanding about APR-246 and inspire us 
how it reactivates mutant p53.  
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Our previous studies have shown, PRIMA-1 and APR-246 convert to MQ, the active 
compound, covalently binds to cysteines in p53 core domain. However, which cysteines are 
the targets remains unclear. In paper III, we showed that the Michael acceptor activity is 
essential for the binding of MQ to p53. Lack of this activity MQ failed to stabilize and refold 
p53 protein. MQ is an electrophile prone to react with nucleophiles. Thereby thiol group in 
cysteine is a prime target. Based on the crystal structure of p53, we know that p53 has 10 
cysteines with various solvent accessibility in the core domain. Cys277 and Cys182 are on 
the surface of p53, which could be easily reached by MQ, followed by Cys229. Cys124 has 
been reported plays a key role in APR-246 mediated mutant p53 reactivation. By Cys to Ala 
substitution at these sites, we found that Cys277 is a prime binding site for MQ and it is 
important for MQ mediated thermostabilization of p53 core domain. Of course cysteines are 
buried in the hydrophobic core can be exposed in certain condition. We have shown that all 
ten cysteines can be reached when the concentration of PRIMA-1 is up to 5mM, however,  
core domains with C277A substitution were not able to be stabilized by increasing MQ 
concentration indicating Cys277 is crucial for MQ mediated p53 thermostabilization. 
Subsequently we studied the role of cysteine Cys124 and Cys277 on mutant p53 reactivation 
by MQ in living tumor cell. The side chain of cysteine is much bigger than alanine. Does this 
substitution have any effect on wild type p53 activity? We observed C124A and C277A 
mutations did not affect wild-type p53 tumor suppressor activity but abolished APR-246 
induced apoptosis and p53 target gene activation, indicating Cys124 and Cys277 are 
important for APR-246 mediated tumor suppression. Although it has been shown that APR-
246 induces cell death in FLO-1 cells, carrying C277F, it mainly due to inhibition of 
SLC7A11 resulting in ROS induced cell death.  
In paper II, we found that the ability of MQ to react with cysteines is needed for mutant p53 
reactivation. Interestingly, several other mutant p53 targeting compounds, CP31398, MIRA-
1, STIMA-1, PK11077, are also have thiol reactivity. In paper IV, we studied the relationship 
between thiol reactivity and mutant p53 reactivation activity. We found that strong thiol 
reactivity leads to toxicity and only mild activity is required for mutant p53 reactivation. 
Various chemical functional groups are associated with different properties for mutant p53 
reactivation. Desired biological and biophysical goals for mutant p53 reactivation are 
possible to be achieved by the elaborate design of thiol-reactive functional groups.  
Altogether, a better understanding of p53 structure and exact mechanisms of current mutant 
p53 reactivating molecules will inspire us and give us new insight to facilitate the design of 
more potent p53-selective compounds and the development of rational drugs for cancer 
treatment.  
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Yihai Cao, Peiqun Ye, Bin Zhou, Hai Bo, Qiang Chen, Jiang Yu, Qing Zhang, Qilin Fu, 
Yanhao Su, Yan Wang, Hong Zhang, Xuechao Wei and all other members from our 
association. It is my honor to be a member of such nice team. I hope everything goes well to 
our association.  
Thanks to all my friends I may not mentioned here. You altogether made me a great time 
during my PhD.  
 
致我亲爱的家人 （To my dearest family） 
非常感谢我的爸爸妈妈，感谢你们的抚养和无私的爱。你们永远是我坚强的后盾和温
暖的港湾，我知道无论我面临什么样的困难你们都会义无反顾的支持和鼓励我。 我
爱你们。 
奶奶您是我们家的顶梁柱，是您把我们一大家人团结在了一起，给我们一个温暖的大
家庭。家和万事兴，希望您健康长寿。感谢我们兄弟们，我们虽然是表兄弟，但是我
们胜似亲兄弟。感谢我所有的亲人们，能和你们成为一家人真好。 
感谢我的妻子胡芳的父母和哥嫂。感谢岳父岳母生养了胡芳，让我娶到这么好的妻子。
感谢哥哥和嫂子对岳父岳母的照顾，让胡芳能安心的在国外陪我。 
特别感谢我的妻子胡芳，我们的结合是上天的安排，是缘分把你从意大利带到了我的
身边。你的出现让我不再漂泊，有了安定的感觉。你细心的照顾和你的理解让我有了
更好的环境来完成我的学业。非常感谢你为我们家增添了新的人口，宇瑞的出生让我
们家里更加兴旺，让我觉得我自己现在责任更重了，但更有为了我们生活更加美满而
奋斗的动力。 
米豆，感谢你的到来，我会和妈妈一起好好爱你，陪你成长。 我们是最幸福的一家
人！ 
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